Upon TGF-β signalling activation, a series of processes occur that can lead to cancer development, and TGF-β signalling can increase drug resistance in tumour cells by mediating epithelial-to-mesenchymal transition (EMT) [25, 26]. This evidence concerns the gene TGFB1 and cancer.